Breaking News Instant updates and real-time market news.

DB

Deutsche Bank

$18.38

-0.65 (-3.42%)

, C

Citi

$59.59

-0.78 (-1.29%)

07:20
03/21/17
03/21
07:20
03/21/17
07:20

Deutsche Bank may be fined over foreign exchange trades, Bloomberg reports

Deutsche Bank (DB) disclosed in a filing Monday that the CFTC has closed its foreign exchange investigation of the bank, and the DOJ, Criminal Division, Fraud Section, has closed its criminal inquiry concerning possible violations of federal criminal law in connection with the foreign exchange markets. However, the Federal Reserve and the New York Department of Financial Services, which had their own probes as well, are in the final stages of their own reviews of the bank's conduct in the foreign exchange market to determine what fines, if any, the bank should pay, according to Bloomberg, citing a person familiar with the matter. Currency investigations lead to five other big banks - Citi (C), JPMorgan (JPM), Barclays (BCS), Royal Bank of Scotland (RBS) and UBS (UBS) - to plead guilty in 2015 in connection with a DOJ probe and Deutsche was the largest participant in the foreign exchange market to escape Justice Department action, though the bank still has to contend with a civil suit against it and 15 other banks, the report added. Reference Link

DB

Deutsche Bank

$18.38

-0.65 (-3.42%)

C

Citi

$59.59

-0.78 (-1.29%)

BCS

Barclays

$11.19

-0.18 (-1.58%)

JPM

JPMorgan

$90.03

-0.65 (-0.72%)

RBS

RBS

$5.92

-0.12 (-1.99%)

UBS

UBS

$15.79

-0.25 (-1.56%)

  • 13

    Apr

  • 14

    Jul

  • 25

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

DB Deutsche Bank
$18.38

-0.65 (-3.42%)

01/06/17
01/06/17
UPGRADE
Target $67

Outperform
Luxoft upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Moshe Katri upgraded Luxoft (LXFT) to Outperform from Neutral to reflect not only an improving spending outlook for the Financial Services sector, but also spending improvements at UBS (UBS) and Deutsche Bank (DB), which collectively account for roughly 43% of the company's revenue base. He also raised his price target on the shares to $67 from $62.
12/19/16
SBSH
12/19/16
DOWNGRADE
SBSH
Sell
Deutsche Bank downgraded to Sell from Neutral at Citi
Citi analyst Andrew Coombs downgraded Deutsche Bank to Sell saying the shares have run "too far, too fast." Since the U.S. election, the stock is up 41%, Coombs tells investors in a research note. The further the share price rises, the less dilutive any future potential capital raise becomes, the analyst writes. He raised his price target for Deutsche shares to EUR 17 from EUR 15.
09/30/16
09/30/16
NO CHANGE

Correction: Deutsche Bank credit upgraded to Neutral at BofA/Merrill
BofA/Merrill upgraded Deutsche Bank's credit to Neutral, not the equity.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
DoJ will not destabilize Deutsche Bank, says Cowen
Cowen analyst Jaret Seiberg sees little practical or political upside for the Justice Department to press Deutsche Bank for a penalty that is so large it could destabilize the bank and create a new financial crisis. He expects the penalty for violations related to mortgage-backed securities to be structured below the speculated $14B that seems to have alarmed the market. Seiberg adds both sides have incentives to reach a deal quickly.
C Citi
$59.59

-0.78 (-1.29%)

02/02/17
SBSH
02/02/17
DOWNGRADE
Target $83
SBSH
Neutral
Citi downgrades Ralph Lauren to Neutral on CEO departure
Citi analyst Kate McShane downgraded Ralph Lauren to Neutral from Buy saying the departure of CEO Stefan Larsson feels like a "giant step back." The CEO change, coupled with a lack of transparency, brings uncertainty to the company's long-term growth strategy, McShane tells investors in a post-earnings research note. She believes finding a replacement could be challenging since the new CEO's vision still has to fit with that of Mr. Lauren. The analyst cut her price target for the shares to $83 from $114. In midday trading, Ralph Lauren is down 11%, or $9.99, to $77.38.
02/01/17
BERN
02/01/17
NO CHANGE
BERN
Citi Mexico exposure appears 'manageable,' says Bernstein
Noting that the Trump Administration is in the process of changing U.S. policies towards Mexico, Bernstein analyst John Mcdonald reports that Citi obtains 8%-9% of its revenue from the country. Still, the analyst believes that Citi's exposure to Mexico "looks manageable, short of a severe economic pullback in the region." McDonald says that Citi's "diversified international exposure and Banamex's long history of operating successfully in Mexico" limit the bank's risk in the country. He keeps a $68 price target and an Outperform rating on the shares.
02/01/17
MSCO
02/01/17
NO CHANGE
MSCO
Overweight
Citi offers most compelling value, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck, said Citi is her top pick and the biggest beneficiary of financial regulation, given its complex global footprint and the largest excess capital versus in the group. Graseck believes Citi's exposure to Mexico and potential $3B in DTA writedowns are manageable and believes fully optimizing capital could drive a 20% increase in earnings. The analyst said Citi offers the most compelling value and reiterates her Overweight rating and $70 price target price target on shares.
03/03/17
EVER
03/03/17
DOWNGRADE
Target $63
EVER
In Line
Citi downgraded to In Line from Buy at Evercore ISI
Evercore ISI changed its rating system to Outperform, In Line and Underperform. Analyst Glenn Schorr said Citi has been executing well and will continue to improve but downgraded shares to In Line. He believes shares will not keep pace with large bank peers given investor preference for less EM exposure, less Mexico, better US rate leverage, and potential for book loss related to lower US tax rates. Schorr's price target on Citi goes to $63 from $62
BCS Barclays
$11.19

-0.18 (-1.58%)

01/30/17
01/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Colgate-Palmolive (CL) downgraded to Neutral from Buy at Citi with analyst Wendy Nicholson saying the sales the "breadth of the top-line weakness" in the company's fourth quarter results is "very disconcerting." Even with the 5% post-earnings pullback, Colgate shares are still not cheap, Nicholson tells investors in a research note. She lowered her price target for the shares to $70 from $76. 2. Air Products (APD) downgraded to Neutral from Outperform at Baird with analyst David Manthey saying he believes the catalyst that led to identifiable margin improvement last quarter may have substantially played out and the company is now more exposed to sluggish economic trends that have underpinned his cautious thinking on Praxair (PX). Manthey lowered his price target to $140 from $146 on Air Products shares. 3. Barclays (BCS) downgraded to Sell from Hold at Berenberg with analyst Peter Richardson citing valuation and high investment banking expectations reflected in shares. 4. Symantec (SYMC) reinstated with a Neutral from Buy at Citi with analyst Walter Pritchard downgrading Symantec (SYMC) to Neutral from Buy after reinstating coverage of the name. The analyst sees "weaker strategic merit" in the company's LifeLock (LOCK) acquisition relative to the Blue Coat deal. He also believes success is being priced in with investors looking for $2.00-plus in earnings power. Pritchard raised his price target for Symantec shares to $29 from $26.50. 5. CONSOL (CNX) downgraded to Hold from Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/17/17
03/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Adobe (ADBE) upgraded to Buy from Hold at Wunderlich with analyst Ryan Macdonald citing the company's better than expected first quarter results. The analyst raised his price target for the shares to $145 from $115. 2. L Brands (LB) upgraded to Outperform from Market Perform at FBR Capital with analyst Susan Anderson saying her survey work shows that Victoria Secret has not lost share over the past year and that same-store-sales will be better than expected in the second half of 2017. 3. Vertex (VRTX) upgraded to Outperform from Market Perform at JMP Securities with analyst Liisa Bayko saying the company's triple combo data this year could expand its cystic fibrosis patient pool by greater than 50%. Positive triple combo data could make Vertex a takeover target, Bayko adds. 4. Dean Foods (DF) upgraded to Overweight from Neutral at JPMorgan with analyst Ken Goldman raising his estimates to reflect lower raw dairy costs. The outlook for Dean's largest input, Class I milk, has softened in recent months, Goldman tells investors in a research note. The analyst raised his price target for the shares to $22 from $20. 5. Barclays (BCS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/16/17
MSCO
03/16/17
UPGRADE
MSCO
Overweight
Barclays upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Christopher Manners upgraded Barclays to Overweight with an increased price target of 280p.
01/30/17
BREN
01/30/17
DOWNGRADE
BREN
Sell
Barclays downgraded to Sell from Hold at Berenberg
Berenberg analyst Peter Richardson downgraded Barclays to Sell citing valuation and high investment banking expectations reflected in shares.
JPM JPMorgan
$90.03

-0.65 (-0.72%)

01/17/17
01/17/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Neutral from Buy at UBS with analyst Eric Sheridan downgrading Twitter after he lowered his advertising revenue estimates for 2017 and 2018 to reflect lower advertising ARPU paired with muted core MAU growth. Sheridan lowered his price target to $18 from $22 on Twitter shares. 2. JPMorgan (JPM) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Brian Kleinhanzl saying he does not see near-term earnings catalysts to move JPMorgan's returns and earnings meaningfully higher absent tax reform or broad-scale deregulation and is downgrading the stock to Market Perform from Outperform as he prefers to take a wait-and-see approach. Kleinhanzl edged his price target on JPMorgan shares up to $89 from $88. 3. Chipotle (CMG) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe saying that his attendance at the ICR Conference underscored the difficult environment hitting many operating companies, including Chipotle. 4. Nordstrom (JWN) downgraded to Hold from Buy at Stifel with with analyst Richard Jaffe saying he believes that the company's holiday sales were weaker than previously expected. 5. OUTFRONT Media (OUT) downgraded to Neutral from Buy at Goldman with analyst Drew Borst citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/20/17
CHLM
01/20/17
NO CHANGE
Target $10
CHLM
Buy
CPI Card may benefit from Amazon, Chase metal credit cards, says Craig-Hallum
Craig-Hallum analyst Brad Berning notes that Amazon's (AMZN) announcement that it is upping its cash back program to 5% on its new Visa (V) Prime Rewards cards contained a statement "buried within it" that Chase (JPM) would issue metal cards on its behalf. With Chase Sapphire and now Amazon Signature Rewards issuing metal credit cards, the analyst believes "the race is on" for issuers to differentiate themselves for key valuable customers. CPI Card Group (PMTS) previously announced that it would start taking orders in Q1 on this new product line, Berning points out, adding that he believes the greater adoption of metal cards makes it more likely that CPI Card Group will be able to get involved. He reiterates a Buy rating and $10 price target on CPI Card Group's shares.
02/07/17
DAIW
02/07/17
UPGRADE
DAIW
Outperform
JPMorgan upgraded to Outperform from Hold at Daiwa
02/24/17
02/24/17
UPGRADE
Target $140

Outperform
Intuit upgraded to Outperform at Credit Suisse
As previously reported, Credit Suisse analyst Michael Nemeroff upgraded Intuit (INTU) to Outperform from Neutral given his expectations for a normal close to the 2016 tax season, in which he expects the company to at least maintain its share of the tax prep market and continued strong growth in its small business segment, particularly given new and expanded partnerships with financial institutions such as JPMorgan Chase (JPM), Wells Fargo (WFC), and others. The analyst also raised his price target on Intuit's shares to $140 from $109.
RBS RBS
$5.92

-0.12 (-1.99%)

03/02/17
03/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) upgraded to Neutral from Underperform at Credit Suisse with analyst Edward Westlake saying that after underperformance versus the S&P, the stock has option value. The analyst also raised his price target on the shares to $83 from $78. 2. RBS (RBS) upgraded to Buy from Hold at Berenberg. 3. Windstream (WIN) upgraded to Hold from Underperform at Jefferies with analyst Scott Goldman saying he sees less risk to estimates following management's 2017 guidance. The analyst upped his price target for the shares to $7.50 from $6. 4. Sarepta (SRPT) upgraded to Outperform from Market Perform at Leerink with analyst Joseph Schwartz saying the stock now reflects "reasonable expectations" for the Exondys launch. Management's new revenue guidance looks "highly conservative," Schwartz tells investors in a research note. The analyst believes share upside could come from Exondys 51 approval in Europe and/or successful development of follow-on antisense candidates. He raised his price target for Sarepta shares to $47 from $27. 5. Estee Lauder (EL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stephanie Wissink saying the growth is de-risked following the guidance reset. The analyst is "bullish" on the prospects for double digit earnings growth for investors that can look into FY18. She raised her price target for the shares to $95 from $81. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/02/17
BREN
03/02/17
UPGRADE
BREN
Buy
RBS upgraded to Buy from Hold at Berenberg
03/02/17
BREN
03/02/17
UPGRADE
BREN
Buy
RBS upgraded to Buy from Hold at Berenberg
Price target 275p.
02/07/17
DBAB
02/07/17
UPGRADE
DBAB
Hold
RBS upgraded to Hold from Sell at Deutsche Bank
UBS UBS
$15.79

-0.25 (-1.56%)

01/11/17
SOCG
01/11/17
UPGRADE
SOCG
Buy
UBS upgraded to Buy from Hold at Societe Generale
02/07/17
BOFA
02/07/17
UPGRADE
Target $17
BOFA
Neutral
UBS upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson upgraded UBS to Neutral saying negative catalysts have played out.
02/07/17
02/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Buy from Neutral at Citi with analyst Robyn Karnauskas saying the Alzheimer's Phase 2 data already reported and no Phase 3 results until 2019/20, upside in the stock rests on the stability of Biogen's multiple sclerosis business and success of the Spinraza launch in spinal muscular atrophy. 2. Caterpillar (CAT) upgraded to Overweight from Equal Weight at Barclays with analyst Robert Wertheimer saying investors likely will never get a chance to buy the company's revenue with as much upside as in 2017. 3. Sysco (SYY) upgraded to Overweight from Neutral at JPMorgan with analyst John Ivankoe saying the shares should be bought in the low $50s. He raised his price target for the shares to $57 from $55. 4. Nokia (NOK) upgraded to Overweight from Equal Weight at Morgan Stanley. 5. UBS (UBS) upgraded to Neutral from Underperform at BofA/Merrill with analyst Andrew Stimpson saying negative catalysts have played out. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

06:05
05/29/17
05/29
06:05
05/29/17
06:05
General news
WTI crude futures are off by 0.2% »

WTI crude futures are off…

03:10
05/29/17
05/29
03:10
05/29/17
03:10
General news
FX Update: The dollar majors have been plying narrow ranges »

FX Update: The dollar…

03:05
05/29/17
05/29
03:05
05/29/17
03:05
General news
Fed's Williams: three hikes this year still make sense. »

Fed's Williams:…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

, MJN

Mead Johnson

$89.29

0.1 (0.11%)

15:32
05/28/17
05/28
15:32
05/28/17
15:32
Conference/Events
Mead Johnson to host special shareholder meeting »

Special Shareholder…

RBGLY

Reckitt Benckiser

$20.53

0.04 (0.20%)

MJN

Mead Johnson

$89.29

0.1 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

PHH

PHH Corp.

$13.58

0.06 (0.44%)

15:25
05/28/17
05/28
15:25
05/28/17
15:25
Conference/Events
PHH Corp. to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TPIV

TapImmune

$3.71

-0.03 (-0.80%)

14:37
05/28/17
05/28
14:37
05/28/17
14:37
Conference/Events
TapImmune to hold a business update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SCOR

comScore

$24.80

-0.15 (-0.60%)

14:35
05/28/17
05/28
14:35
05/28/17
14:35
Conference/Events
comScore to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BMY

Bristol-Myers

$53.97

-0.42 (-0.77%)

14:12
05/28/17
05/28
14:12
05/28/17
14:12
Conference/Events
Bristol-Myers to hold a pharmaceutical update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

  • 24

    Sep

LOXO

Loxo Oncology

$47.44

-0.06 (-0.13%)

14:10
05/28/17
05/28
14:10
05/28/17
14:10
Conference/Events
Loxo Oncology to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 04

    Jun

  • 06

    Jun

ADRO

Aduro Biotech

$10.05

-0.15 (-1.47%)

14:07
05/28/17
05/28
14:07
05/28/17
14:07
Conference/Events
Aduro Biotech to host analyst and investor meeting »

Management hosts special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

ELGX

Endologix

$4.73

-0.05 (-1.05%)

14:06
05/28/17
05/28
14:06
05/28/17
14:06
Conference/Events
Endologix to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

  • 03

    Jun

TSRO

Tesaro

$149.11

-4.08 (-2.66%)

14:02
05/28/17
05/28
14:02
05/28/17
14:02
Conference/Events
Tesaro to hold an analyst and investor briefing »

Management hosts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 03

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$60.35

-0.09 (-0.15%)

13:57
05/28/17
05/28
13:57
05/28/17
13:57
Conference/Events
IntercontinentalExchange to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 07

    Jun

CPA

Copa Holdings

$111.69

0.2 (0.18%)

13:48
05/28/17
05/28
13:48
05/28/17
13:48
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

CAH

Cardinal Health

$73.10

-0.34 (-0.46%)

13:31
05/28/17
05/28
13:31
05/28/17
13:31
Conference/Events
Cardinal Health to hold a meeting »

Dublin Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BPMX

BioPharmX

$0.64

0.0089 (1.41%)

13:26
05/28/17
05/28
13:26
05/28/17
13:26
Conference/Events
BioPharmX holds state of acne symposium »

Management provides…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$80.63

-0.72 (-0.89%)

13:20
05/28/17
05/28
13:20
05/28/17
13:20
Conference/Events
Novartis to hold a meeting »

Meet the Management Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 26

    Jun

CNC

Centene

$74.57

-0.68 (-0.90%)

, MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

12:34
05/27/17
05/27
12:34
05/27/17
12:34
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$74.57

-0.68 (-0.90%)

MOH

Molina Healthcare

$66.87

-0.21 (-0.31%)

HUM

Humana

$232.25

0.02 (0.01%)

AET

Aetna

$145.57

0.34 (0.23%)

ANTM

Anthem

$183.08

1.58 (0.87%)

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

WCG

WellCare

$172.97

0.15 (0.09%)

CI

Cigna

$161.32

-0.33 (-0.20%)

BX

Blackstone

$32.58

0.11 (0.34%)

NUE

Nucor

$58.15

-0.22 (-0.38%)

X

U.S. Steel

$19.74

-0.51 (-2.52%)

STLD

Steel Dynamics

$33.71

-0.73 (-2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 16

    Jun

21:00
05/26/17
05/26
21:00
05/26/17
21:00
General news
Breaking General news story  »

San Francisco Federal…

20:00
05/26/17
05/26
20:00
05/26/17
20:00
General news
Breaking General news story  »

San Francisco Federal…

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.